To include your compound in the COVID-19 Resource Center, submit it here.

Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday.

Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers